Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1128-1136

  Bonnefoi, Hervé ^a   Litiere S ^b   Piccart, M ^c   MacGrogan, G ^a   Fumoleau, P ^d   Brain, E ^e   Petit, T ^f   Rouanet, P ^g   Jassem, J ^h   Moldovan, C ⁱ   Bodmer, A ^j,k   Zaman, K ^l   Cufer, T ^m,n   Campone, M ^o,p   Luporsi, E ^q   Malmstrom P ^r,s   Werutsky, G ^b   Bogaerts, J ^b   Bergh, J ^t,u   Cameron, D A ^v,w  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b EORTC DATA CENTER   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e INSTITUT CURIE   (France)

^f CENTRE PAUL STRAUSS   (France)

^g CENTRE VAL D AURELLE   (France)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^k SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^l LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^m INSTITUTE OF ONCOLOGY   (Slovenia)

ⁿ UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^o CENTRE RENÉ GAUDUCHEAU   (France)

^p CENTRE PAUL PAPIN   (France)

^q CENTRE ALEXIS VAUTRIN   (France)

^r LUND UNIVERSITY   (Sweden)

^s LUND UNIVERSITY HOSPITAL   (Sweden)

^t Swedish Breast Cancer Group (SweBCG)   (Sweden)

^u KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^v UNIVERSITY OF EDINBURGH   (United Kingdom)

^w Anglo Celtic Cooperative Oncology Group   (United Kingdom)

more..

Author keywords

Breast cancer; Landmark analysis; Neoadjuvant chemotherapy; Pathological complete response; TP53

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PROTEIN P53; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG RESPONSE; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903277747     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu118     Document Type: Article

References (15)

1. Bonnefoi H, Piccart M, Bogaerts J et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011; 12: 527-539.
2. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366: 2438-2441.
3. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
4. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
5. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
6. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
7. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014 February 14 [epub ahead of print], http://dx.doi.org/10.1016/S0140-6736(13) 62422-8.
8. Untch M, Fasching PA, Konecny GE et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29: 3351-3357.
9. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
10. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26: 3913-3915.
11. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the S. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
12. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.
13. Esserman LJ, Berry DA, DeMichele A et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30: 3242-3249.
14. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol 2013; 31: 2963-2969.
15. Provenzano E, Vallier AL, Champ R et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer 2013; 108: 866-872.